Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on modern management of frailty

LIVE: Thursday 17th October 2024, 18:00-19:30 (CEST)

Frailty has a significant impact on health and wellbeing, especially in older adults. Join our experts to understand the factors that contribute to the development of frailty and find out how to manage the condition and reduce the risk of disability, dependency, and mortality.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in:

Open Access 01-12-2023 | Research

Uncovering the mechanism of resveratrol in the treatment of diabetic kidney disease based on network pharmacology, molecular docking, and experimental validation

Authors: Shengnan Chen, Bo Li, Lei Chen, Hongli Jiang

Published in: Journal of Translational Medicine | Issue 1/2023

Login to get access

Abstract

Background

Diabetic kidney disease (DKD) has been the leading cause of chronic kidney disease in developed countries. Evidence of the benefits of resveratrol (RES) for the treatment of DKD is accumulating. However, comprehensive therapeutic targets and underlying mechanisms through which RES exerts its effects against DKD are limited.

Methods

Drug targets of RES were obtained from Drugbank and SwissTargetPrediction Databases. Disease targets of DKD were obtained from DisGeNET, Genecards, and Therapeutic Target Database. Therapeutic targets for RES against DKD were identified by intersecting the drug targets and disease targets. GO functional enrichment analysis, KEGG pathway analysis, and disease association analysis were performed using the DAVID database and visualized by Cytoscape software. Molecular docking validation of the binding capacity between RES and targets was performed by UCSF Chimera software and SwissDock webserver. The high glucose (HG)-induced podocyte injury model, RT-qPCR, and western blot were used to verify the reliability of the effects of RES on target proteins.

Results

After the intersection of the 86 drug targets and 566 disease targets, 25 therapeutic targets for RES against DKD were obtained. And the target proteins were classified into 6 functional categories. A total of 11 cellular components terms and 27 diseases, and the top 20 enriched biological processes, molecular functions, and KEGG pathways potentially involved in the RES action against DKD were recorded. Molecular docking studies showed that RES had a strong binding affinity toward PPARA, ESR1, SLC2A1, SHBG, AR, AKR1B1, PPARG, IGF1R, RELA, PIK3CA, MMP9, AKT1, INSR, MMP2, TTR, and CYP2C9 domains. The HG-induced podocyte injury model was successfully constructed and validated by RT-qPCR and western blot. RES treatment was able to reverse the abnormal gene expression of PPARA, SHBG, AKR1B1, PPARG, IGF1R, MMP9, AKT1, and INSR.

Conclusions

RES may target PPARA, SHBG, AKR1B1, PPARG, IGF1R, MMP9, AKT1, and INSR domains to act as a therapeutic agent for DKD. These findings comprehensively reveal the potential therapeutic targets for RES against DKD and provide theoretical bases for the clinical application of RES in the treatment of DKD.
Literature
1.
Magliano DJ, Boyko EJ, Committee IDF DATES, IDF Diabetes Atlas [M]. Idf diabetes atlas. Brussels: International Diabetes Federation; 2021.
2.
Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, et al. Diabetic kidney disease: a report from an ADA consensus conference. Diabetes Care. 2014;37:2864–83.PubMedPubMedCentralCrossRef
3.
Koye DN, Magliano DJ, Nelson RG, Pavkov ME. The global epidemiology of diabetes and kidney disease. Adv Chronic Kidney Dis. 2018;25:121–32.PubMedCrossRef
4.
Pan X, Lin X, Huang X, Xu J, Ye L, Zhang T, et al. The Burden of diabetes-related chronic kidney disease in China from 1990 to 2019. Front Endocrinol (Lausanne). 2022;13: 892860.PubMedCrossRef
5.
Dai X, Liao R, Liu C, Liu S, Huang H, Liu J, et al. Epigenetic regulation of TXNIP-mediated oxidative stress and NLRP3 inflammasome activation contributes to SAHH inhibition-aggravated diabetic nephropathy. Redox Biol. 2021;45: 102033.PubMedPubMedCentralCrossRef
6.
7.
Roborel de Climens A, Pain E, Boss A, Shaunik A. Understanding reasons for treatment discontinuation, attitudes and education needs among people who discontinue type 2 diabetes treatment: results from an online patient survey in the USA and UK. Diabetes Ther. 2020;11:1873–81.PubMedPubMedCentralCrossRef
8.
Blahova J, Martiniakova M, Babikova M, Kovacova V, Mondockova V, Omelka R. Pharmaceutical drugs and natural therapeutic products for the treatment of type 2 diabetes mellitus. Pharmaceuticals. 2021;14:806.PubMedPubMedCentralCrossRef
9.
Kushwaha K, Sharma S, Gupta J. Metabolic memory and diabetic nephropathy: beneficial effects of natural epigenetic modifiers. Biochimie. 2020;170:140–51.PubMedCrossRef
10.
Khatoon E, Banik K, Harsha C, Sailo BL, Thakur KK, Khwairakpam AD, et al. Phytochemicals in cancer cell chemosensitization: current knowledge and future perspectives. Semin Cancer Biol. 2022;80:306–39.PubMedCrossRef
11.
Huang DD, Shi G, Jiang Y, Yao C, Zhu C. A review on the potential of Resveratrol in prevention and therapy of diabetes and diabetic complications. Biomed Pharmacother. 2020;125: 109767.PubMedCrossRef
12.
Behroozaghdam M, Dehghani M, Zabolian A, Kamali D, Javanshir S, Hasani Sadi F, et al. Resveratrol in breast cancer treatment: from cellular effects to molecular mechanisms of action. Cell Mol Life Sci. 2022;79:539.PubMedCrossRef
13.
Sattarinezhad A, Roozbeh J, Shirazi Yeganeh B, Omrani GR, Shams M. Resveratrol reduces albuminuria in diabetic nephropathy: a randomized double-blind placebo-controlled clinical trial. Diabetes Metab. 2019;45:53–9.PubMedCrossRef
14.
Brasnyó P, Molnár GA, Mohás M, Markó L, Laczy B, Cseh J, et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr. 2011;106:383–9.PubMedCrossRef
15.
Zhou S, Ai Z, Li W, You P, Wu C, Li L, et al. Deciphering the pharmacological mechanisms of taohe-chengqi decoction extract against renal fibrosis through integrating network pharmacology and experimental validation in vitro and in vivo. Front Pharmacol. 2020;11:425.PubMedPubMedCentralCrossRef
16.
Guo W, Huang J, Wang N, Tan HY, Cheung F, Chen F, et al. Integrating network pharmacology and pharmacological evaluation for deciphering the action mechanism of herbal formula zuojin pill in suppressing hepatocellular carcinoma. Front Pharmacol. 2019;10:1185.PubMedPubMedCentralCrossRef
17.
Wu Z, Ma H, Liu Z, Zheng L, Yu Z, Cao S, et al. wSDTNBI: a novel network-based inference method for virtual screening. Chem Sci. 2022;13:1060–79.PubMedCrossRef
18.
19.
Jiang L, Liu X, Hu X, Gao L, Zeng H, Wang X, et al. METTL3-mediated m(6)A modification of TIMP2 mRNA promotes podocyte injury in diabetic nephropathy. Mol Ther. 2022;30:1721–40.PubMedPubMedCentralCrossRef
20.
21.
Zhong Y, Lee K, Deng Y, Ma Y, Chen Y, Li X, et al. Arctigenin attenuates diabetic kidney disease through the activation of PP2A in podocytes. Nat Commun. 2019;10:4523.PubMedPubMedCentralCrossRef
22.
Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2017;46:D1074–82.PubMedCentralCrossRef
23.
Daina A, Michielin O, Zoete V. SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules. Nucleic Acids Res. 2019;47:W357–64.PubMedPubMedCentralCrossRef
24.
Piñero J, Ramírez-Anguita JM, Saüch-Pitarch J, Ronzano F, Centeno E, Sanz F, et al. The DisGeNET knowledge platform for disease genomics: 2019 update. Nucleic Acids Res. 2020;48:D845–55.PubMed
25.
Safran M, Dalah I, Alexander J, Rosen N, Iny Stein T, Shmoish M, et al. GeneCards Version 3: the human gene integrator. Database (Oxford). 2010;2010:baq020.PubMedPubMedCentralCrossRef
26.
27.
Mi H, Ebert D, Muruganujan A, Mills C, Albou LP, Mushayamaha T, et al. PANTHER version 16: a revised family classification, tree-based classification tool, enhancer regions and extensive API. Nucleic Acids Res. 2021;49:D394-d403.PubMedCrossRef
28.
Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47:D607–13.PubMedCrossRef
29.
Dennis G, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, et al. DAVID: database for annotation, visualization, and integrated discovery. Genome Biol. 2003;4:P3.PubMedCrossRef
30.
Kim S, Thiessen PA, Bolton EE, Chen J, Fu G, Gindulyte A, et al. PubChem substance and compound databases. Nucleic Acids Res. 2016;44:D1202–13.PubMedCrossRef
31.
32.
33.
UniProt Consortium. UniProt: the universal protein knowledgebase in 2021. Nucleic Acids Res. 2021;49:D480–9.CrossRef
34.
35.
36.
Yang RC, Zhu XL, Zhang HQ, Li WD. Study of resveratrol suppressing TGF-beta1 induced transdifferentiation of podocytes. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2013;33:1677–82.PubMed
37.
Chen S, Li B, Chen L, Jiang H. Identification and validation of immune-related biomarkers and potential regulators and therapeutic targets for diabetic kidney disease. BMC Med Genomics. 2023;16:90.PubMedPubMedCentralCrossRef
38.
Sangeetha MK, Vallabi DE, Sali VK, Thanka J, Vasanthi HR. Sub-acute toxicity profile of a modified resveratrol supplement. Food Chem Toxicol. 2013;59:492–500.PubMedCrossRef
39.
Huang X, Pearce R, Omenn GS, Zhang Y. Identification of 13 guanidinobenzoyl- or aminidinobenzoyl-containing drugs to potentially inhibit TMPRSS2 for COVID-19 treatment. Int J Mol Sci. 2021;22:7060.PubMedPubMedCentralCrossRef
40.
Murugan NA, Muvva C, Jeyarajpandian C, Jeyakanthan J, Subramanian V. Performance of force-field- and machine learning-based scoring functions in ranking MAO-B protein-inhibitor complexes in relevance to developing Parkinson’s therapeutics. Int J Mol Sci. 2020;21:7648.PubMedPubMedCentralCrossRef
41.
Kadela-Tomanek M, Jastrzębska M, Marciniec K, Chrobak E, Bębenek E, Boryczka S. Lipophilicity, pharmacokinetic properties, and molecular docking study on SARS-CoV-2 target for betulin triazole derivatives with attached 1,4-quinone. Pharmaceutics. 2021;13:781.PubMedPubMedCentralCrossRef
42.
Brawerman GM, Kereliuk SM, Brar N, Cole LK, Seshadri N, Pereira TJ, et al. Maternal resveratrol administration protects against gestational diabetes-induced glucose intolerance and islet dysfunction in the rat offspring. J Physiol. 2019;597:4175–92.PubMedCrossRef
43.
Calleri E, Pochetti G, Dossou KSS, Laghezza A, Montanari R, Capelli D, et al. Resveratrol and its metabolites bind to PPARs. ChemBioChem. 2014;15:1154–60.PubMedPubMedCentralCrossRef
44.
Park HS, Lim JH, Kim MY, Kim Y, Hong YA, Choi SR, et al. Resveratrol increases AdipoR1 and AdipoR2 expression in type 2 diabetic nephropathy. J Transl Med. 2016;14:176.PubMedPubMedCentralCrossRef
45.
Zhang Y, Luo Z, Ma L, Xu Q, Yang Q, Si L. Resveratrol prevents the impairment of advanced glycosylation end products (AGE) on macrophage lipid homeostasis by suppressing the receptor for AGE via peroxisome proliferator-activated receptor gamma activation. Int J Mol Med. 2010;25:729–34.PubMed
46.
Hajizadeh-Sharafabad F, Sahebkar A, Zabetian-Targhi F, Maleki V. The impact of resveratrol on toxicity and related complications of advanced glycation end products: a systematic review. BioFactors. 2019;45:651–65.PubMedCrossRef
47.
Zhang T, Chi Y, Kang Y, Lu H, Niu H, Liu W, et al. Resveratrol ameliorates podocyte damage in diabetic mice via SIRT1/PGC-1α mediated attenuation of mitochondrial oxidative stress. J Cell Physiol. 2019;234:5033–43.PubMedCrossRef
48.
Li Y, Fang L, Yan Y, Wang Z, Wu Z, Jia Q, et al. Association between human SHBG gene polymorphisms and risk of PCOS: a meta-analysis. Reprod Biomed Online. 2021;42:227–36.PubMedCrossRef
49.
Zhu JL, Chen Z, Feng WJ, Long SL, Mo ZC. Sex hormone-binding globulin and polycystic ovary syndrome. Clin Chim Acta. 2019;499:142–8.PubMedCrossRef
50.
Saez-Lopez C, Brianso-Llort L, Torres-Torronteras J, Simó R, Hammond GL, Selva DM. Resveratrol increases hepatic SHBG expression through human constitutive androstane receptor: a new contribution to the French paradox. Sci Rep. 2017;7:12284.PubMedPubMedCentralCrossRef
51.
Qasem RJ. The estrogenic activity of resveratrol: a comprehensive review of in vitro and in vivo evidence and the potential for endocrine disruption. Crit Rev Toxicol. 2020;50:439–62.PubMedCrossRef
52.
Khayami R, Hashemi SR, Kerachian MA. Role of aldo-keto reductase family 1 member B1 (AKR1B1) in the cancer process and its therapeutic potential. J Cell Mol Med. 2020;24:8890–902.PubMedPubMedCentralCrossRef
53.
Balestri F, Poli G, Piazza L, Cappiello M, Moschini R, Signore G, et al. Dissecting the activity of catechins as incomplete aldose reductase differential inhibitors through kinetic and computational approaches. Biology. 2022;11:1324.PubMedPubMedCentralCrossRef
54.
Wu T-T, Chen Y-Y, Chang H-Y, Kung Y-H, Tseng C-J, Cheng P-W. AKR1B1-induced epithelial–mesenchymal transition mediated by RAGE-oxidative stress in diabetic cataract lens. Antioxidants. 2020;9:27.CrossRef
55.
Dong R, Yu J, Yu F, Yang S, Qian Q, Zha Y. IGF-1/IGF-1R blockade ameliorates diabetic kidney disease through normalizing Snail1 expression in a mouse model. Am J Physiol Endocrinol Metab. 2019;317:E686–98.PubMedCrossRef
56.
Kong YL, Shen Y, Ni J, Shao DC, Miao NJ, Xu JL, et al. Insulin deficiency induces rat renal mesangial cell dysfunction via activation of IGF-1/IGF-1R pathway. Acta Pharmacol Sin. 2016;37:217–27.PubMedPubMedCentralCrossRef
57.
Vanamala J, Reddivari L, Radhakrishnan S, Tarver C. Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p53 signaling pathways. BMC Cancer. 2010;10:238.PubMedPubMedCentralCrossRef
58.
Ohlsson C, Kley N, Werner H, Leroith D. p53 regulates insulin-like growth factor-I (IGF-I) receptor expression and IGF-I-induced tyrosine phosphorylation in an osteosarcoma cell line: interaction between p53 and Sp1. Endocrinology. 1998;139:1101–7.PubMedCrossRef
59.
Li G, Zhang J, Liu D, Wei Q, Wang H, Lv Y, et al. Identification of Hub genes and potential ceRNA networks of diabetic nephropathy by weighted gene co-expression network analysis. Front Genet. 2021;12: 767654.PubMedPubMedCentralCrossRef
60.
Li SY, Huang PH, Yang AH, Tarng DC, Yang WC, Lin CC, et al. Matrix metalloproteinase-9 deficiency attenuates diabetic nephropathy by modulation of podocyte functions and dedifferentiation. Kidney Int. 2014;86:358–69.PubMedCrossRef
61.
Kim YS, Sull JW, Sung HJ. Suppressing effect of resveratrol on the migration and invasion of human metastatic lung and cervical cancer cells. Mol Biol Rep. 2012;39:8709–16.PubMedCrossRef
62.
Walker J, Schueller K, Schaefer LM, Pignitter M, Esefelder L, Somoza V. Resveratrol and its metabolites inhibit pro-inflammatory effects of lipopolysaccharides in U-937 macrophages in plasma-representative concentrations. Food Funct. 2014;5:74–84.PubMedCrossRef
63.
Shao AW, Wu HJ, Chen S, Ammar AB, Zhang JM, Hong Y. Resveratrol attenuates early brain injury after subarachnoid hemorrhage through inhibition of NF-κB-dependent inflammatory/MMP-9 pathway. CNS Neurosci Ther. 2014;20:182–5.PubMedCrossRef
64.
Gweon EJ, Kim SJ. Resveratrol attenuates matrix metalloproteinase-9 and -2-regulated differentiation of HTB94 chondrosarcoma cells through the p38 kinase and JNK pathways. Oncol Rep. 2014;32:71–8.PubMedCrossRef
65.
Razali N, Agarwal R, Agarwal P, Froemming GRA, Tripathy M, Ismail NM. IOP lowering effect of topical trans-resveratrol involves adenosine receptors and TGF-β2 signaling pathways. Eur J Pharmacol. 2018;838:1–10.PubMedCrossRef
66.
Takamiya Y, Fukami K, Yamagishi S, Kaida Y, Nakayama Y, Obara N, et al. Experimental diabetic nephropathy is accelerated in matrix metalloproteinase-2 knockout mice. Nephrol Dial Transplant. 2013;28:55–62.PubMedCrossRef
67.
McKenna M, Balasuriya N, Zhong S, Li SS, O’Donoghue P. Phospho-form specific substrates of protein kinase B (AKT1). Front Bioeng Biotechnol. 2020;8: 619252.PubMedCrossRef
68.
69.
Sun X, Cao Z, Ma Y, Shao Y, Zhang J, Yuan G, et al. Resveratrol attenuates dapagliflozin-induced renal gluconeogenesis via activating the PI3K/Akt pathway and suppressing the FoxO1 pathway in type 2 diabetes. Food Funct. 2021;12:1207–18.PubMedCrossRef
70.
Hou Y, Wang K, Wan W, Cheng Y, Pu X, Ye X. Resveratrol provides neuroprotection by regulating the JAK2/STAT3/PI3K/AKT/mTOR pathway after stroke in rats. Genes Dis. 2018;5:245–55.PubMedPubMedCentralCrossRef
71.
Wu Z, Huang A, Yan J, Liu B, Liu Q, Zhang J, et al. Resveratrol ameliorates cardiac dysfunction by inhibiting apoptosis via the PI3K/Akt/FoxO3a pathway in a rat model of diabetic cardiomyopathy. J Cardiovasc Pharmacol. 2017;70:184–93.PubMedCrossRef
72.
Hsieh TC, Lin CY, Bennett DJ, Wu E, Wu JM. Biochemical and cellular evidence demonstrating AKT-1 as a binding partner for resveratrol targeting protein NQO2. PLoS ONE. 2014;9: e101070.PubMedPubMedCentralCrossRef
Metadata
Title
Uncovering the mechanism of resveratrol in the treatment of diabetic kidney disease based on network pharmacology, molecular docking, and experimental validation
Authors
Shengnan Chen
Bo Li
Lei Chen
Hongli Jiang
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2023
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-023-04233-0

Other articles of this Issue 1/2023

Journal of Translational Medicine 1/2023 Go to the issue

Research

Identifying the natural products in the treatment of atherosclerosis by increasing HDL-C level based on bioinformatics analysis, molecular docking, and in vitro experiment

Research

β-catenin-IRP2-primed iron availability to mitochondrial metabolism is druggable for active β-catenin-mediated cancer

Review

Maternal microbiota and gestational diabetes: impact on infant health

Research

Association between lipid-A-producing oral bacteria of different potency and fractional exhaled nitric oxide in a Norwegian population-based adult cohort

Research

Discovery of extracellular vesicle-delivered miR-185-5p in the plasma of patients as an indicator for advanced adenoma and colorectal cancer

Research

WGX50 mitigates doxorubicin-induced cardiotoxicity through inhibition of mitochondrial ROS and ferroptosis

EASD 2024

‘Noninferior’ reduction of type 1 diabetes HbA1c by weekly insulin efsitora alfa

Weekly treatment with insulin efsitora is noninferior to daily insulin degludec for the reduction of HbA1c in adults with type 1 diabetes, show the findings of the QWINT-5 trial.

Read more

Weight loss with new obesity drug amycretin

Tirzepatide significantly reduces UACR in individuals with obesity and type 2 diabetes

Liraglutide reduces BMI for young children with obesity

» View more highlights on the EASD 2024 hub page

2024 ESC Congress

Noise pollution dangerous for heart health

Two studies underscore the adverse impact of noise pollution on the risk for and prognosis after myocardial infarction.

Read more

Post-TAVI follow up: deploying virtual assistants

Antihypertensives: more effective at morning or night?

Low Lp(a) levels unlikely to increase the risk of diabetes

» View more highlights on the 2024 ESC Congress hub page

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more
Image Credits